The offer came in well below what you expected. Here’s how to figure out why, and what you can actually change.
You built a model. You ran the numbers. You walked into the room with a figure in your head, and the term sheet came back at roughly half of it. Now you’re staring at the gap, wondering whether the investor is wrong, you’re naive, or the whole exercise is just theater.
It’s none of those. The gap is real, and it’s almost always telling you something specific about your company. The problem is that most founders don’t have a clean way to read it. They treat valuation as a black box, a single number that pops out of a spreadsheet, when it’s actually the product of just two forces. Understand those two forces, and the gap stops being an insult and becomes a diagnosis.
Valuation is only ever two questions
Strip away the methods, the multiples, and the jargon, and every startup valuation is answering exactly two questions.
How much could this company be worth if it works? That’s expected return: the cash it could generate, the exit value it could reach, the size of the prize.
How likely is it to actually get there? That’s risk, the probability that the plan survives contact with reality.
Value is what you get when you put those two together. A massive potential return discounted by a high chance of failure can land at the same number as a modest return that’s nearly certain. This is not an Equidam invention. It’s the logic underneath every valuation method ever built, from a corporate DCF to a back-of-napkin angel guess. The reason it feels invisible is that most write-ups never separate the two. They hand you a list of “factors that affect valuation” (team, market, traction, IP, financials) as if they’re all the same kind of thing.
They’re not. And separating them is the whole game.
Every input is a proxy for one of the two
Take the long checklist of things investors care about and sort each one into the right bucket. Most founders never do this, and it’s where the clarity comes from.
The qualitative stuff is almost all risk. Your team’s track record, the strength of your business model, the size and reachability of your market, your IP position, your early traction: none of these tell an investor how much money you’ll make. They tell the investor how likely you are to make it. A second-time founder with a relevant exit doesn’t have a bigger addressable market than a first-timer. They have a higher probability of executing against it. Signed LOIs don’t change your pricing. They raise the odds your revenue assumptions are real. Every qualitative input is the investor asking the same thing: how confident should I be that this happens?
The financial projections are return. Your revenue forecast, your margins, your terminal value, the exit scenario: that’s the size of the prize. It’s the answer to “if this works, how big is the payout?”
Equidam puts it more cleanly than I can paraphrase: “If the DCF models set the goalposts you are aiming for, and the VC method shows the size of the prize, then the qualitative methods show how likely you are to score.” The financials define the upside. The qualitative assessment defines the probability of reaching it. Risk and return, in different clothes.
Once you see it this way, the reason serious valuation tools blend several methods instead of picking one stops being mysterious. You need methods that measure return and methods that measure risk, because the number depends on both. Equidam runs five methods for exactly this reason: two qualitative (the Scorecard Method and Checklist Method, which price risk) and three financial (DCF with Long-Term Growth, DCF with Multiple, and the Venture Capital Method, which price return).
Why the weighting shifts as you grow
If valuation reflects both risk and return, then the balance between the two should change as a company matures. And it does.
At the idea stage, there’s barely any return to measure. Your financial model is a hypothesis dressed up as a spreadsheet. What an investor can actually assess is the risk: is this a credible team, attacking a real market, with a defensible wedge? So early-stage value leans heavily on the qualitative side, with the financial methods carrying much less weight.
Move to a growth-stage company with real revenue and the picture flips. The risk has largely resolved (the team executes, the market responded, the model works) so the question becomes “how big is this going to get?” That’s a return question, and the weighting shifts toward the financial methods, with the qualitative methods fading out as the company matures. At full maturity, a company is valued almost entirely on the cash it produces, because there’s little uncertainty left to discount.
This is the synthesis the “qualitative vs. quantitative” debate keeps missing. It was never an either/or. Early on you lean on qualitative methods because risk is the dominant force and there’s no return to measure yet. Later you lean on financials because the risk has burned off and return is all that’s left. You use both, re-weighted by stage, because that’s how the two forces actually trade off over a company’s life.
Why investors price risk so harshly
Founders often feel the numbers are stacked against them. They kind of are, and the reason is in the data.
The venture model runs on a power law. VenCap looked at 11,350 startups backed by 259 funds between 1986 and 2018 and found that roughly half were valued below cost, while only 1.1% (121 companies) returned an entire fund on their own. When a handful of bets carry the whole portfolio and the majority lose money, every individual deal has to be priced as if it might be a loser, because statistically it probably is.
That’s why the return hurdles look so steep. Seed investors effectively underwrite for around 100x, Series A investors for 10–15x, and later-stage investors for 3–5x. Those multiples aren’t greed. They’re the math of survival in a business where most companies fail, and they fall as you move up the stages precisely because the risk falls with them.
And failure is mostly a risk story, not a return story. CB Insights’ analysis of VC-backed companies that shut down since 2023 found that running out of cash was the most-cited reason, but that’s the final symptom, not the cause. The root causes sit upstream: poor product-market fit (cited for 43% of failures in that dataset), bad timing (29%), and unsustainable unit economics (19%). Every one of those is a risk signal an investor is trying to read before they wire the money.
The mechanism that turns all this into a number is the discount rate, the haircut applied to your future returns to account for the chance they never arrive. In Equidam’s framework, the venture capital method runs at a discount rate of roughly 60% for an early-stage startup, easing toward a floor near 48% as the company matures. That single number is where risk gets translated into euros. A 60% discount rate doesn’t mean your business is bad. It reflects how often companies at your stage don’t make it. As you de-risk, that rate falls, and your valuation rises even if your projections never change.
You can watch this happen in the benchmarks. In 2025, seed pre-money valuations commonly landed between $10M and $20M, with a median around $16M, while Series A pushed to an all-time-high median near $49.3M, often on 5–15x ARR multiples. The jump from seed to Series A isn’t mostly about a bigger market or a grander vision. It’s roughly the same vision with more of the risk resolved.
The diagnostic: is it a risk problem or a return problem?
When your valuation comes in low, run this test before you argue with anyone.
Picture your best realistic case. Not the dream, the credible upside, the one you’d defend to a skeptic. Then ask: in that scenario, how big is the company? How large is the exit?
If even your best case is modest, you have a return problem. The size of the prize isn’t big enough to clear the hurdle, or your projections aren’t credible enough to be believed. Investors aren’t doubting you so much as the ceiling on the outcome.
If your best case is genuinely huge but investors won’t fund it at your number, you have a risk problem. They believe the prize exists. They don’t yet believe you’ll reach it. The upside is there, but the probability they’re assigning is too low.
Most founders assume they have a return problem, that they need to tell a bigger story. Often it’s the opposite. The story is fine; the proof is missing. Sort yourself into the right bucket first, because the fixes are completely different.
If it’s a return problem
You’re working on the size and credibility of the upside.
Reframe the market honestly but ambitiously. A lot of founders undersell their own ceiling by anchoring to a narrow initial segment. If there’s a defensible path to adjacent markets, model it. Don’t leave it as a throwaway line in the deck.
Fix the unit economics in the model, not just the slide. Margins, payback, and the shape of the cohort curve drive terminal value. Small, defensible improvements to the steady-state economics compound hard in a DCF.
Make the projections ambitious and defensible at the same time. Sandbagged forecasts cap your return. Fantasy forecasts get discounted to zero the moment an investor stops believing them. The goal is the most ambitious number you can actually defend line by line. Equidam has a whole piece on which projection approaches help and which backfire.
Reprice the exit scenario. If your comparables are stale or too conservative, the prize looks smaller than it is. Pull current, relevant multiples and let the financials reflect them.
If it’s a risk problem
You don’t need a bigger story. You need to move the probability, which means moving the qualitative score.
Close the proof gaps that map to failure causes. Remember what actually kills startups: weak product-market fit, unsustainable unit economics, getting outpaced on timing. Bring evidence against each. Retention and cohort data attack the product-market-fit doubt directly. Early revenue or signed LOIs convert “they might buy” into “they’re buying.”
Make the team a smaller question mark. A single senior hire in the area investors quietly worry about, a technical co-lead or a commercial leader who’s scaled before, can move the risk assessment more than another quarter of slow growth.
Hit the milestones that retire specific risks. A granted patent, a regulatory clearance, a key integration going live: each one removes a named uncertainty from the model. That is the lever most founders never realize they’re holding. De-risking lowers the discount rate, and a lower discount rate raises your valuation even when your projections stay exactly where they are.
Set the right number, not just a high one
There’s a failure mode on the other side, too. Pushing for a number your risk and return can’t support doesn’t just risk a down round later. It makes the current raise harder. Finro’s work on the cost of overvaluation is a useful reminder that an inflated price extends your fundraise, scares off disciplined investors, and sets a bar you then have to clear before the next round. The risk/return lens is how you find the number you can actually defend: high enough to be fair to you, grounded enough to close.
When founders and investors disagree on valuation, it’s rarely that one side is irrational. It’s that they’re weighting the two forces differently. Usually the founder is pricing the return they can see and the investor is pricing the risk they can’t yet rule out. Naming which force you’re debating turns a standoff into a solvable conversation.
We don’t have perfect insight into how any single investor weights these things on any given day; psychology and market mood always play a role. But the structure is consistent, and it’s drawn from real benchmarks. Equidam’s numbers come from a base of 160,000+ valued companies and 30,000+ public comparables, tailored to 90 countries and 600+ industries. The two forces are always there, underneath.
Where to start
If you want to see which force is dragging your own number, and test what happens when you de-risk or revise the upside, that’s exactly what Equidam is built to show you. Run your valuation, watch how the qualitative and financial methods pull in different directions, and find out whether your gap is a risk problem or a return problem before you walk into the room.